IMPROVED ECG MODELS FOR ESTIMATION OF LEFT-VENTRICULAR HYPERTROPHY PROGRESSION AND REGRESSION INCIDENCE BY REDEFINITION OF THE CRITERIA FOR A SIGNIFICANT CHANGE IN LEFT-VENTRICULAR HYPERTROPHY STATUS

被引:0
|
作者
ZHOU, SH
RAUTAHARJU, PM
PRINEAS, R
NEATON, J
CROW, R
CALHOUN, H
FURBERG, C
COHEN, J
机构
[1] UNIV ALBERTA, EPICORE CTR,DIV CARDIOL,HERITAGE MED RES BLDG, ROOM, EDMONTON T6G 2S2, AB, CANADA
[2] UNIV ALBERTA, CTR CARDIAC EPIDEMIOL COORDINAT & RES, EDMONTON T6G 2E1, ALBERTA, CANADA
[3] UNIV MIAMI, DEPT EPIDEMIOL & PUBL HLTH, MIAMI, FL 33152 USA
[4] UNIV MINNESOTA, CTR MULTIPLE RISK FACTOR INTERVENT TRIAL COORDINAT, MINNEAPOLIS, MN 55455 USA
[5] UNIV MINNESOTA, DIV EPIDEMIOL, MINNEAPOLIS, MN 55455 USA
[6] WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27103 USA
[7] ST LOUIS UNIV, MED CTR, ST LOUIS, MO 63103 USA
关键词
CLASSIFICATION-SYSTEM; CLINICAL-TRIALS; HEALTH; RISK; MASS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Three sets of left ventricular hypertrophy (LVH) criteria were evaluated in terms of their utility for LVH progression and regression incidence estimation. Incidence comparisons were performed with and without taking short-term variability into consideration using electrocardiographic records taken at the baseline and the first annual follow-up examination of 11,969 men, aged 37 to 55 years, at the baseline of the Multiple Risk Factor Intervention Trial. Short-term total technical and biologic variability (95% range) was determined from the records of 104 men invited for a repeat electrocardiographic recording at 2-week or shorter intervals from the first recording. The results indicated that after elimination of the false fraction due to normal variability, the residual incidence estimates are so low that their utility and statistical power in monitoring changes in LVH status is very limited. It is concluded that a redefinition of LVH progression and regression criteria is needed to enhance their utility in clinical trials.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 50 条
  • [41] INSULIN AND LEFT-VENTRICULAR HYPERTROPHY
    UUSITUPA, M
    VANNINEN, E
    JOURNAL OF INTERNAL MEDICINE, 1993, 233 (06) : 503 - 504
  • [42] LEFT-VENTRICULAR HYPERTROPHY IN EMPHYSEMA
    EDWARDS, CW
    THORAX, 1974, 29 (01) : 75 - 80
  • [43] PHYSIOPATHOLOGY OF LEFT-VENTRICULAR HYPERTROPHY
    WAEBER, B
    WEBER, R
    BRUNNER, HR
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 1995, 88 : 9 - 14
  • [44] LEFT-VENTRICULAR HYPERTROPHY AND HYPERTENSION
    CALVERT, JF
    AMERICAN FAMILY PHYSICIAN, 1992, 46 (02) : 379 - 381
  • [45] PHYSIOLOGICAL LEFT-VENTRICULAR HYPERTROPHY
    SHAPIRO, LM
    BRITISH HEART JOURNAL, 1984, 52 (02): : 130 - 135
  • [46] Microcirculation and left-ventricular hypertrophy
    Angeli, Fabio
    Reboldi, Gianpaolo
    Verdecchia, Paolo
    JOURNAL OF HYPERTENSION, 2012, 30 (03) : 477 - 481
  • [47] CYANOSIS AND LEFT-VENTRICULAR HYPERTROPHY
    HANCOCK, EW
    HOSPITAL PRACTICE, 1992, 27 (09): : 53 - 54
  • [48] LEFT-VENTRICULAR HYPERTROPHY AND HYPERTENSION
    DEVEREUX, RB
    DESIMONE, G
    GANAU, A
    KOREN, MJ
    MENSAH, GA
    ROMAN, MJ
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 1993, 15 (06) : 1025 - 1032
  • [49] GENETIC AND LEFT-VENTRICULAR HYPERTROPHY
    CAMBIEN, F
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 1995, 88 : 25 - 26
  • [50] VERAPAMIL AND LEFT-VENTRICULAR HYPERTROPHY
    THOM, CM
    CLINICAL PHARMACY, 1991, 10 (05): : 333 - 333